Comparison of adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema: A global network study
{{output}}
Purpose: Patients with diabetic macular oedema (DMO) are susceptible to renal injury, raising the risks of acute kidney injury (AKI) and end-stage renal disease (ESRD) associated with anti-VEGF therapies. We aimed to compare the ... ...
